Publication: 251

Publication: 251

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).

PubMed

DOI

Google Scholar

Citation:: Lung Cancer vol 60 (2) 200-7

Year:: 2008
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Respiratory
Sec. Committees:

Pharmas:
Grants:: CA-25224, CA-35101, CA-35103, CA-35113, CA-35119, CA-35195, CA-35269, CA-35431, CA-35448, CA-37404, CA-37417, CA-60276, CA-63848, CA-63849

Corr. Author:
Authors:: Elizabeth A Johnson Randolph S Marks Sumithra J Mandrekar Shauna L Hillman Mark D Hauge Mitchel D Bauman Edward J Wos Dennis F Moore John W Kugler Harold E Windschitl David L Graham Albert M Bernath Tom R Fitch Gamini S Soori James R Jett Alex A Adjei Edith A Perez

Networks:

Study: NCCTG-972451
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms, Male, Middle Aged, Placebos, Quality of Life, Triazoles